iTeos Therapeutics (ITOS) Competitors $8.32 +0.19 (+2.34%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ITOS vs. TSHA, VXRT, NK, CALT, MESO, ANIP, RCKT, ARDX, AVDL, and APLTShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Taysha Gene Therapies (TSHA), Vaxart (VXRT), NantKwest (NK), Calliditas Therapeutics AB (publ) (CALT), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), and Applied Therapeutics (APLT). These companies are all part of the "medical" sector. iTeos Therapeutics vs. Taysha Gene Therapies Vaxart NantKwest Calliditas Therapeutics AB (publ) Mesoblast ANI Pharmaceuticals Rocket Pharmaceuticals Ardelyx Avadel Pharmaceuticals Applied Therapeutics iTeos Therapeutics (NASDAQ:ITOS) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Which has more volatility & risk, ITOS or TSHA? iTeos Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Does the MarketBeat Community believe in ITOS or TSHA? Taysha Gene Therapies received 67 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 77.08% of users gave iTeos Therapeutics an outperform vote while only 77.04% of users gave Taysha Gene Therapies an outperform vote. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes3777.08% Underperform Votes1122.92% Taysha Gene TherapiesOutperform Votes10477.04% Underperform Votes3122.96% Does the media prefer ITOS or TSHA? In the previous week, iTeos Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for iTeos Therapeutics and 3 mentions for Taysha Gene Therapies. iTeos Therapeutics' average media sentiment score of 0.75 beat Taysha Gene Therapies' score of -0.06 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iTeos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ITOS or TSHA? iTeos Therapeutics currently has a consensus price target of $31.50, indicating a potential upside of 278.61%. Taysha Gene Therapies has a consensus price target of $6.63, indicating a potential upside of 168.22%. Given iTeos Therapeutics' higher probable upside, research analysts clearly believe iTeos Therapeutics is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in ITOS or TSHA? 97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ITOS or TSHA more profitable? iTeos Therapeutics has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. iTeos Therapeutics' return on equity of -20.11% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% Taysha Gene Therapies -229.67%-106.36%-49.16% Which has higher valuation & earnings, ITOS or TSHA? Taysha Gene Therapies has lower revenue, but higher earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M8.68-$112.64M-$3.15-2.64Taysha Gene Therapies$9.92M51.05-$111.57M$0.633.92 SummaryiTeos Therapeutics beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$303.96M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E Ratio-2.6445.50105.0417.81Price / Sales8.68392.401,235.79158.52Price / CashN/A169.3840.3536.29Price / Book0.484.597.086.50Net Income-$112.64M-$41.63M$119.58M$226.22M7 Day Performance1.09%2.61%2.25%4.03%1 Month Performance-5.99%-2.47%-2.34%4.92%1 Year Performance-14.23%28.24%33.95%29.30% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics3.5107 of 5 stars$8.32+2.3%$31.50+278.6%-14.2%$303.96M$35M-2.6490TSHATaysha Gene Therapies3.7863 of 5 stars$2.18+8.5%$6.63+203.9%+34.2%$446.77M$15.45M3.46180VXRTVaxart2.573 of 5 stars$0.60-1.6%$3.00+400.6%-16.8%$106.33M$7.38M-1.46109Analyst RevisionPositive NewsNKNantKwestN/A$4.88-8.8%N/A+20.2%$533.06M$40,000.00-6.96160High Trading VolumeCALTCalliditas Therapeutics AB (publ)0.2735 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsMESOMesoblast1.2372 of 5 stars$10.18-1.5%$11.50+13.0%+277.2%$1.18B$5.90M0.0080Gap DownANIPANI Pharmaceuticals4.2863 of 5 stars$55.78+1.2%$77.33+38.6%+10.1%$1.17B$486.82M-101.56642Positive NewsRCKTRocket Pharmaceuticals4.4402 of 5 stars$13.00-0.3%$51.00+292.3%-35.6%$1.17BN/A-4.73240Analyst ForecastAnalyst RevisionARDXArdelyx4.012 of 5 stars$5.14+4.5%$10.42+102.5%+23.2%$1.17B$251.85M-17.15267Insider TradeAVDLAvadel Pharmaceuticals2.3401 of 5 stars$11.67+8.5%$24.43+109.4%+2.0%$1.12B$27.96M-14.77154APLTApplied Therapeutics4.4388 of 5 stars$9.32-1.2%$12.50+34.1%+406.6%$1.08B$9.99M0.0030 Related Companies and Tools Related Companies TSHA Competitors VXRT Competitors NK Competitors CALT Competitors MESO Competitors ANIP Competitors RCKT Competitors ARDX Competitors AVDL Competitors APLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITOS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
